Cellectar Biosciences (NASDAQ:CLRB) is set to issue its quarterly earnings data after the market closes on Wednesday, May 9th.
Cellectar Biosciences (NASDAQ:CLRB) last released its quarterly earnings data on Wednesday, March 21st. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.11). On average, analysts expect Cellectar Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Cellectar Biosciences stock opened at $1.10 on Monday. The stock has a market capitalization of $19.13, a price-to-earnings ratio of -1.03 and a beta of 0.74. Cellectar Biosciences has a 1 year low of $1.03 and a 1 year high of $2.06.
In other news, CEO James V. Caruso sold 34,000 shares of the company’s stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $1.20, for a total value of $40,800.00. Following the completion of the sale, the chief executive officer now owns 213,548 shares of the company’s stock, valued at approximately $256,257.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 8.74% of the stock is currently owned by corporate insiders.
CLRB has been the subject of several research reports. Zacks Investment Research raised shares of Cellectar Biosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. ValuEngine raised shares of Cellectar Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
Cellectar Biosciences Company Profile
Cellectar Biosciences, Inc, a clinical stage biopharmaceutical company, engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company offers CLR 131, a PDC cytotoxic radioisotope product candidate, which is in Phase I clinical study for the treatment of relapse or refractory multiple myeloma, as well as in Phase II clinical study for the treatment of B-cell malignancies; and CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease.
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.